Susquehanna International Group, LLP Syros Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.69 - $1.21 $139,646 - $244,887	202,386 Added 768.71%	228,714 $220,000
Q1 2022 May 16, 2022	SELL	$1.02 - $3.8 $142,486 - $530,833	-139,693 Reduced 84.14%	26,328 $31,000
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $153,976 - $220,101	-47,232 Reduced 22.15%	166,021 $541,000
Q3 2021 Nov 15, 2021	BUY	$4.08 - $5.66 $272,307 - $377,759	66,742 Added 45.55%	213,253 $953,000
Q2 2021 Aug 11, 2021	BUY	$5.01 - $7.48 $280,920 - $419,418	56,072 Added 62.0%	146,511 $798,000
Q1 2021 May 17, 2021	SELL	$7.19 - $14.95 $54,953 - $114,262	-7,643 Reduced 7.79%	90,439 $676,000
Q4 2020 Feb 16, 2021	BUY	$6.66 - $14.66 $178,761 - $393,489	26,841 Added 37.68%	98,082 $1.07 Million
Q3 2020 Nov 16, 2020	BUY	$8.69 - $14.47 $421,456 - $701,780	48,499 Added 213.26%	71,241 $629,000
Q2 2020 Aug 14, 2020	SELL	$5.21 - $11.03 $57,221 - $121,142	-10,983 Reduced 32.57%	22,742 $242,000
Q1 2020 May 15, 2020	BUY	$4.46 - $9.2 $69,562 - $143,492	15,597 Added 86.04%	33,725 $200,000
Q4 2019 Feb 14, 2020	BUY	$4.52 - $10.1 $10,626 - $23,745	2,351 Added 14.9%	18,128 $125,000
Q3 2019 Nov 14, 2019	BUY	$7.14 - $11.65 $10,010 - $16,333	1,402 Added 9.75%	15,777 $164,000
Q2 2019 Aug 16, 2019	BUY	$5.5 - $9.75 $79,062 - $140,156	14,375 New	14,375 $133,000
Q1 2019 May 15, 2019	SELL	$5.51 - $9.59 $145,618 - $253,444	-26,428 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$5.55 - $11.34 $146,675 - $299,693	26,428 New	26,428 $147,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.